PAHC
Phibro Animal Health Corporation NASDAQ$54.68
Mkt Cap $2.2B
52w Low $18.89
86.9% of range
52w High $60.08
50d MA $53.85
200d MA $42.57
P/E (TTM)
46.1x
EV/EBITDA
11.8x
P/B
7.8x
Debt/Equity
2.7x
ROE
21.8%
P/FCF
24.7x
RSI (14)
—
ATR (14)
—
Beta
0.69
50d MA
$53.85
200d MA
$42.57
Avg Volume
292.2K
About
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattl…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | AMC | 0.69 | 0.87 | +26.1% | 41.00 | +5.3% | +22.0% | +29.4% | +26.5% | +26.2% | +25.7% | — |
| Nov 5, 2025 | AMC | 0.59 | 0.73 | +23.7% | 41.15 | +0.3% | +4.6% | +6.3% | +11.4% | +10.2% | +10.1% | — |
| Aug 27, 2025 | AMC | 0.52 | 0.57 | +9.6% | 32.20 | +17.7% | +19.4% | +15.1% | +13.9% | +18.6% | +21.3% | — |
| May 7, 2025 | AMC | 0.52 | 0.63 | +21.2% | 19.39 | -0.4% | +14.7% | +15.9% | +26.4% | +26.9% | +20.5% | — |
| Feb 5, 2025 | AMC | 0.40 | 0.54 | +35.0% | 22.37 | +6.8% | +9.9% | +5.9% | +17.2% | +16.8% | +10.0% | — |
| Nov 7, 2024 | AMC | 0.25 | 0.35 | +40.0% | 23.50 | -0.6% | +1.5% | +8.7% | +6.6% | +7.5% | +6.0% | — |
| Aug 28, 2024 | AMC | 0.34 | 0.41 | +20.6% | 20.81 | -5.6% | +3.2% | +0.9% | -4.5% | -5.6% | -6.7% | — |
| May 8, 2024 | AMC | 0.29 | 0.31 | +6.9% | 17.18 | -0.9% | +3.0% | +2.2% | +5.4% | +6.0% | +6.2% | — |
| Feb 7, 2024 | AMC | 0.27 | 0.33 | +22.2% | 10.67 | +5.0% | +7.4% | +8.4% | +14.1% | +6.2% | +12.0% | — |
| Nov 8, 2023 | AMC | 0.21 | 0.14 | -33.3% | 12.04 | -14.2% | -18.5% | -19.8% | -18.9% | -15.5% | -12.8% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 7 | JP Morgan | Maintains | Overweight → Overweight | — | $43.04 | $43.17 | +0.3% | +1.7% | +6.5% | +5.3% | +5.3% | +3.9% |
| Aug 29 | BofA Securities | Maintains | Underperform → Underperform | — | $38.46 | $38.25 | -0.5% | -3.6% | -4.6% | -0.7% | +1.6% | +2.6% |
| Jul 7 | JP Morgan | Upgrade | Neutral → Overweight | — | $28.00 | $29.63 | +5.8% | +6.8% | +7.6% | +12.1% | +11.2% | +10.0% |
| Jun 25 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $24.77 | $25.00 | +0.9% | -0.1% | +1.4% | +3.6% | +3.1% | +7.5% |
| May 8 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $19.39 | $19.32 | -0.4% | +14.7% | +15.9% | +26.4% | +26.9% | +20.5% |
| Feb 10 | Barclays | Maintains | Underweight → Underweight | — | $23.69 | $23.86 | +0.7% | +10.7% | +10.3% | +3.8% | +6.3% | +8.8% |
| Dec 17 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $22.64 | $22.63 | -0.0% | -1.3% | -6.1% | -3.7% | -4.2% | -4.4% |
| Nov 12 | Barclays | Maintains | Underweight → Underweight | — | $25.55 | $25.65 | +0.4% | -1.9% | -1.1% | -2.5% | -4.3% | -5.6% |
| Aug 30 | BofA Securities | Maintains | Underperform → Underperform | — | $21.47 | $21.59 | +0.6% | -2.2% | -7.5% | -8.5% | -9.5% | -9.4% |
| May 10 | Barclays | Maintains | Underweight → Underweight | — | $17.70 | $17.82 | +0.7% | -0.8% | +2.3% | +2.9% | +3.1% | +1.6% |
Recent Filings
8-K · 1.01
! Medium
Phibro Animal Health Corporation -- 8-K 1.01: Financing / Debt Agreement
Phibro Animal Health Corporation amended its financing agreement, potentially modifying debt terms or covenants that could affect the company's financial flexibility and borrowing costs for investors.
Apr 30
8-K · 7.01
! Medium
Phibro Animal Health Corporation Class A -- 8-K 7.01: Regulation FD Disclosure
Phibro Animal Health faces a potential product prohibition taking effect in 180 days, which could materially impact sales and operations depending on the ordinance's scope and affected markets.
Apr 27
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
PAHC's executive change could signal leadership instability or strategic repositioning, making investors question management continuity and future company direction during what may be a critical operational period.
Apr 14
8-K
Phibro Animal Health Corporation Class A -- 8-K Filing
Phibro Animal Health raised full-year guidance after exceeding expectations with faster-than-anticipated adoption of its newly integrated MFA portfolio in Q2 2026.
Feb 4
8-K · 8.01
!! High
Phibro Animal Health Corporation Class A -- 8-K 8.01: Material Event / Announcement
Phibro Animal Health (PAHC) announced a dividend payment to shareholders, signaling confidence in cash generation and commitment to returning capital to investors.
Feb 3
Data updated apr 26, 2026 6:31pm
· Source: massive.com